Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

FP-LAD

From Wikipedia, the free encyclopedia

Pharmaceutical compound
FP-LAD
Clinical data
Other namesFluoro-PRO-LAD; F-PRO-LAD; Fluoropropyl-LAD; TRALA-16; 6-(3-Fluoropropyl)-6-nor-LSD; (8β)-N,N-Diethyl-6-(3-fluoropropyl)-9,10-didehydroergoline-8-carboxamide
Drug classSerotonin receptor modulator;Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • (6aR,9R)-N,N-diethyl-7-(3-fluoropropyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChemCID
Chemical and physical data
FormulaC22H28FN3O
Molar mass369.484 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)CCCF
  • InChI=1S/C22H28FN3O/c1-3-25(4-2)22(27)16-11-18-17-7-5-8-19-21(17)15(13-24-19)12-20(18)26(14-16)10-6-9-23/h5,7-8,11,13,16,20,24H,3-4,6,9-10,12,14H2,1-2H3/t16-,20-/m1/s1
  • Key:BFFBEQKSDONILF-OXQOHEQNSA-N

FP-LAD, also known asfluoro-PRO-LAD or asTRALA-16, is aserotonin receptor modulator of thelysergamide family related tolysergic acid diethylamide (LSD; METH-LAD).[1] It is specifically afluorinatedderivative ofPRO-LAD (6-propyl-6-nor-LSD) and ananalogue ofFLUORETH-LAD (FE-LAD; 6-ethyl-6-nor-LSD).[1]

The drug has been reported to act as apotentligand of the serotonin5-HT2 receptors.[1] It hadaffinities (Ki) of 0.93 nM at theserotonin5-HT2A receptor, 1.8 nM at the serotonin5-HT2B receptor, and 3.7 nM at the serotonin5-HT2C receptor.[1] FP-LAD was assessed and found to be afull agonist of the serotonin 5-HT2A and 5-HT2C receptors, withEC50Tooltip half-maximal effective concentration andEmaxTooltip maximal efficacy values of 0.48 nM (93%) and 1.7 nM (97%), respectively.[1] It had several-fold greater activational potency than LSD at the serotonin 5-HT2A and 5-HT2C receptors.[1]

Thechemical synthesis of FP-LAD has been described.[1]

FP-LAD waspatented byDaniel Trachsel andMatthias Liechti and colleagues in association withMindMed (Mind Medicine) in 2023.[1] It had also previously been described in an earlier patent by Andrew Kruegel in association withGilgamesh Pharmaceuticals in 2022.[2]Hamilton Morris has described synthesizing FP-LAD and/or1P-FP-LAD withLizard Labs in 2025.[3][4][5] According to Morris, FP-LAD was active but had only about one-fifth of thepotency of LSD.[5]

See also

[edit]

References

[edit]
  1. ^abcdefghUS 2023/0414583, Trachsel D, Liechti ME, Lustenberger F, "Lysergic acid derivatives with modified LSD-like action", published 28 December 2023, assigned to Mind Medicine Inc. 
  2. ^WO 2022226408A1, Kruegel AC, "Novel ergolines and methods of treating mood disorders", published 25 April 2022, assigned to Gilgamesh Pharmaceuticals, Inc.  Example 13: Preparation of (6aR,9R)-N,N-diethyl-7-(cyclopropylmethyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (13) [...]
  3. ^Andrew Callaghan (27 September 2025)."The Fight for Legal Psychedelics (#12)".Channel 5 with Andrew Callaghan (Podcast).YouTube. Event occurs at 1:14:26–1:15:32.[...] I just made a really interesting variant of LSD. I don't know if I have to bleep this out, but it was propyl-fluoro-1-propionyl-nor-LSD. And 6-propylfluoro. [...]
  4. ^Adam Jay Moskowitz (2 October 2025)."Drug Journalist Hamilton Morris on Why All Drugs Should Be Legal".A Cheese Course (Podcast).YouTube. Event occurs at 29:48–31:12.[...]
  5. ^abHamilton Morris (13 July 2025)."POD 128: Dr. Daniel Panaccione on a newly discovered lysergamide producing fungus".The Hamilton Morris Podcast (Podcast). Patreon. Event occurs at ~58:20.

External links

[edit]
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT3–7
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Ergolines
(incl.lysergines)
Clavines
(6,8-dimethylergolines)
Lysergamides
(lysergic acid amides)
Ergopeptines
(peptide ergolines)
Partial ergolines
Related compounds
Natural sources
Retrieved from "https://en.wikipedia.org/w/index.php?title=FP-LAD&oldid=1337935627"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp